Additionally, western blotting confirmed that UBX‐390 administration significantly induced AR protein degradation in the tumor tissues of the VCaP xenograft model, thus indicating that the tumor growth inhibitory effect of UBX‐390 was due to AR degradation (Figure 4E) and demonstrating the anti‐tumor activity of UBX‐390 in vivo (Figure 4C,D). The gene discussed is AR; the disease is neoplasm.